Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $49.46 down -0.64% from its previous closing price of $49.78. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 1.07 million shares were traded. IONS stock price reached its highest trading level at $50.9 during the session, while it also had its lowest trading level at $49.38.
Ratios:
For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.28 and its Current Ratio is at 7.37. In the meantime, Its Debt-to-Equity ratio is 6.64 whereas as Long-Term Debt/Eq ratio is at 6.49.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on July 24, 2024, Upgraded its rating to Outperform and sets its target price to $62 from $53 previously.
Bernstein Upgraded its Underperform to Mkt Perform on June 14, 2024, while the target price for the stock was maintained at $44.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 16 ’24 when KLEIN JOSEPH III sold 12,000 shares for $50.00 per share. The transaction valued at 600,000 led to the insider holds 0 shares of the business.
Diaz Allene M. sold 1,637 shares of IONS for $81,019 on Jul 16 ’24. The Director now owns 15,716 shares after completing the transaction at $49.49 per share. On Jun 17 ’24, another insider, BERTHELSEN SPENCER R, who serves as the Director of the company, sold 16,000 shares for $40.29 each. As a result, the insider received 644,640 and left with 147,257 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 7219428352 and an Enterprise Value of 7030522368. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.29 while its Price-to-Book (P/B) ratio in mrq is 24.33. Its current Enterprise Value per Revenue stands at 9.053 whereas that against EBITDA is -19.826.
Stock Price History:
Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is 12.90%, while the 200-Day Moving Average is calculated to be 7.96%.
Shares Statistics:
For the past three months, IONS has traded an average of 1.35M shares per day and 1277550 over the past ten days. A total of 144.34M shares are outstanding, with a floating share count of 134.16M. Insiders hold about 8.08% of the company’s shares, while institutions hold 96.45% stake in the company. Shares short for IONS as of 1721001600 were 9365346 with a Short Ratio of 6.94, compared to 1718323200 on 8653199. Therefore, it implies a Short% of Shares Outstanding of 9365346 and a Short% of Float of 7.59.
